Form 4: Elevation Oncology CFO Tammy Furlong Reports Stock Transactions

Elevation Oncology's Chief Financial Officer, Tammy Furlong, reported the acquisition of 300 shares and the disposal of 98 shares of common stock on November 15, 2024.

Summary

• Tammy Furlong, the Chief Financial Officer of Elevation Oncology, reported transactions involving the company's common stock on November 15, 2024.
• She acquired 300 shares of common stock through the vesting of restricted stock units (RSUs).
• She also disposed of 98 shares of common stock at a price of $0.5315 per share.
• Following these transactions, Ms. Furlong directly owns 1,410 shares of common stock and 2,700 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of stock transactions by an executive, and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transactions reported are typical for executives who receive stock-based compensation, such as restricted stock units.
• Similar filings are made by executives at comparable companies like Xometry, Inc. and Veracyte, Inc. when they trade company stock.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider trading activity.
• The vesting of restricted stock units is part of the compensation package for the CFO.

Key Dates

Keywords

Elevation Oncology, Tammy Furlong, stock transactions, restricted stock units, Form 4, insider trading, ELEV